Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues-Reference-Cited by-同舟云学术

Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues

Published:2018-07-30 Issue:12 Volume:36 Page:1395-1405
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Danzon Patricia M.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/article/10.1007/s40273-018-0696-4/fulltext.html

Reference52 articles.

1. Danzon PM, Towse AK. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ. 2003;3(3):183–205.

2. Yadav P. Differential pricing for pharmaceuticals. UK Department for International Development. 2010. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/67672/diff-pcing-pharma.pdf . Accessed 12 Jan 2017.

3. Danzon PM, Towse AK, Mestre-Ferrandiz J. Value-Based differential pricing: efficient prices for drugs in a global context. Health Econ. 2013;24(3):238–52.

4. Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):735–41.

5. Towse A, Pistollato M, Mestre-Ferrandiz J, et al. European Union pharmaceutical markets: a case for differential pricing? Int J Econ Bus. 2015;22(2):263–75.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab;PLOS ONE;2024-02-01

2. Patient Welfare Implications of Indication-specific Value-based Pricing of Multi-indication Drugs;Value in Health;2023-12

3. The functions of known to be inaccurate prices in markets: A cross-country comparison of pharmaceutical list pricing;Journal of Business Research;2023-11

4. Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices;Applied Health Economics and Health Policy;2023-09-26

5. Trends in the Cost of Medicines, Consultation Fees and Clinic Visits in Malaysia’s Private Primary Healthcare System: Employer Health Insurance Coverage;Journal of Multidisciplinary Healthcare;2023-06